AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
AMD3100 given in combination with busulfan, fludarabine (and thymoglobulin (ATG) for
unrelated or HLA nonidentical donors) preparative regimen in patients with acute myelogenous
leukemia (AML) / myelodysplastic syndromes (MDS).
This study aims to determine if in AML and MDS patients there is a reduction of malignant
cells and enhanced elimination of the leukemia as assessed by progression free survival.
Secondary goals will be to assess effects on engraftment, graft versus host disease (GVHD)
and immune reconstitution.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Collaborator:
AnorMED
Treatments:
Busulfan Fludarabine Fludarabine phosphate JM 3100 Plerixafor